Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

Matthew D Blunt; Stephen G Ward

doi:10.1016/j.coph.2012.02.015

Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

Matthew D Blunt, Stephen G Ward

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

26 Citations (SciVal)

328 Downloads (Pure)

Abstract

PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.

Original language	English
Pages (from-to)	444-451
Journal	Current Opinion in Pharmacology
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.coph.2012.02.015
Publication status	Published - Aug 2012

Access to Document

10.1016/j.coph.2012.02.015

Ward_COP_2012.pdf
NOTICE: this is the author’s version of a work that was accepted for publication in Current Opinion in Pharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Current Opinion in Pharmacology, 2012, vol 12, issue 4, DOI 10.1016/j.coph.2012.02.015
Accepted author manuscript, 309 KB

Cite this

@article{f2fbce37a84c4b7ea3e96d141c6fbd04,

title = "Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia",

abstract = "PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.",

author = "Blunt, {Matthew D} and Ward, {Stephen G}",

year = "2012",

month = aug,

doi = "10.1016/j.coph.2012.02.015",

language = "English",

volume = "12",

pages = "444--451",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

AU - Blunt, Matthew D

AU - Ward, Stephen G

PY - 2012/8

Y1 - 2012/8

N2 - PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.

AB - PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.

UR - http://www.scopus.com/inward/record.url?scp=84865012034&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1016/j.coph.2012.02.015

U2 - 10.1016/j.coph.2012.02.015

DO - 10.1016/j.coph.2012.02.015

M3 - Article

SN - 1471-4892

VL - 12

SP - 444

EP - 451

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

IS - 4

ER -

Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this